These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20739382)

  • 1. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure.
    Puig-Domingo M; Resmini E; Gomez-Anson B; Nicolau J; Mora M; Palomera E; Martí C; Halperin I; Webb SM
    J Clin Endocrinol Metab; 2010 Nov; 95(11):4973-8. PubMed ID: 20739382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
    Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
    J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
    Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
    Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
    Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of pre-treatment with somatostatin analogs on surgical management of acromegalic patients referred to a single center.
    Bacigaluppi S; Gatto F; Anania P; Bragazzi NL; Rossi DC; Benvegnu G; Nazzari E; Spaziante R; Giusti M; Ferone D; Zona G
    Endocrine; 2016 Mar; 51(3):524-33. PubMed ID: 25982150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
    Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
    Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.
    Duan L; Zhu H; Xing B; Gu F
    BMC Endocr Disord; 2017 Sep; 17(1):55. PubMed ID: 28874187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues.
    Sherlock M; Fernandez-Rodriguez E; Alonso AA; Reulen RC; Ayuk J; Clayton RN; Holder G; Sheppard MC; Bates A; Stewart PM
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1255-63. PubMed ID: 19158203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy.
    Colao A; Pivonello R; Galderisi M; Cappabianca P; Auriemma RS; Galdiero M; Cavallo LM; Esposito F; Lombardi G
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2639-46. PubMed ID: 18445662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly.
    Theodoropoulou M; Tichomirowa MA; Sievers C; Yassouridis A; Arzberger T; Hougrand O; Deprez M; Daly AF; Petrossians P; Pagotto U; Beckers A; Stalla GK
    Int J Cancer; 2009 Nov; 125(9):2122-6. PubMed ID: 19637311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
    Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas.
    Tortora F; Negro A; Grasso LFS; Colao A; Pivonello R; Splendiani A; Brunese L; Caranci F
    Gland Surg; 2019 Sep; 8(Suppl 3):S150-S158. PubMed ID: 31559182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly.
    Ruiz S; Gil J; Biagetti B; Venegas E; Cámara R; Garcia-Centeno R; Gálvez MÁ; Picó A; Maraver S; González I; Abellán P; Trincado P; Herrera M; Olvera P; Xifra G; Bernabeu I; Serra-Soler G; Azriel S; García L; Carvalho D; Jordà M; Valassi E; Puig J; Puig-Domingo M
    Clin Endocrinol (Oxf); 2023 Oct; 99(4):378-385. PubMed ID: 37421211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly.
    Heck A; Ringstad G; Fougner SL; Casar-Borota O; Nome T; Ramm-Pettersen J; Bollerslev J
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):72-8. PubMed ID: 22066905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly.
    Ayuk J; Stewart SE; Stewart PM; Sheppard MC
    J Clin Endocrinol Metab; 2002 Sep; 87(9):4142-6. PubMed ID: 12213862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study.
    Durmuş ET; Atmaca A; Kefeli M; Çalışkan S; Mete O; Aslan K; Fidan M; Çolak R; Durmuş B
    Growth Horm IGF Res; 2022 Dec; 67():101502. PubMed ID: 36115256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Six-month preoperative octreotide treatment in unselected, de novo patients with acromegaly: effect on biochemistry, tumour volume, and postoperative cure.
    Carlsen SM; Svartberg J; Schreiner T; Aanderud S; Johannesen O; Skeie S; Lund-Johansen M; Fougner SL; Bollerslev J;
    Clin Endocrinol (Oxf); 2011 Jun; 74(6):736-43. PubMed ID: 21521254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.